News Releases

Date Title and Summary
Toggle Summary electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum
ROCKAWAY, NJ , Nov. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be available for virtual one-on-one meetings at the Canaccord Genuity MedTech & Diagnostics Forum .
Toggle Summary electroCore Announces Third Quarter 2021 Financial Results
Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 Company to host a conference call and webcast today, November 4, 2021 at 4:30 pm ET ROCKAWAY, N.J. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine
Toggle Summary electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th
ROCKAWAY, NJ , Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November 4, 2021 .
Toggle Summary electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England
ROCKAWAY, NJ , Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled “Non-invasive vagus nerve stimulation for treatment of cluster headache: a retrospective review of
Toggle Summary electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescents ROCKAWAY, NJ , Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended
Toggle Summary electroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance
Third q uarter 2021 revenue expected to be approximately $1.5 million Net cash used to fund operations in the third quarter 2021 of approximately $3.5 million ROCKAWAY, NJ , Oct. 12, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today
Toggle Summary electroCore Announces Acceptance of Motion to Dismiss in the Federal Court Securities Class Action Suit
ROCKAWAY, NJ , Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the federal court securities class action case filed in Trenton, NJ .
Toggle Summary electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
ROCKAWAY, NJ , Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30,
Toggle Summary electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
ROCKAWAY, NJ , Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve
Toggle Summary electroCore to Participate at Upcoming Investor Conferences
ROCKAWAY, NJ , Sept. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference .  The